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THE POTENTIAL BENEFIT OF ESOPHAGEAL SPARING DURING 
PALLIATIVE RADIOTHERAPY FOR LUNG CANCER  
Patrick V Granton, David A Palma, Alexander V Louie 
University of Western Ontario, London, ON 
 
Purpose:  A 2007 meta-analysis of several randomized controlled 
trials assessing optimal doses for palliative lung radiation 
concluded that radiation doses of 35 Gy10 or greater improved 
overall survival at one and two years compared to lower doses at 
the cost of an increased toxicity related to esophagitis. 
Esophageal sparing has been proposed as a mechanism of 
reducing this toxicity. A planning study was initiated to assess 
the potential impact of esophageal-sparing IMRT (ES-IMRT) for 
palliative lung radiotherapy, compared to the current standard 
of care using parallel-opposed pair beams (POP). 
Methods and Materials:  In this institutional research ethics 
board-approved study, patients with lung cancer treated to a 
dose of 30 Gy in 10 fractions between August 2015 and January 
2016 were identified. Additional inclusion criteria required the 
D50 to contain at least 5 cm of esophagus. The radiation 
treatment plans were optimized using ES-IMRT by limiting the 
max esophageal point dose to 80% of the prescription. This was 
achieved by creating a 5 mm ring around the esophagus. If any 
portion of the GTV was within this ring, the coverage was 
compromised such that a point dose could receive as low as 80% 
of the intended prescription. Both the clinical POP and optimized 
ES-IMRT plans were evaluated for the likelihood of esophagitis (≥ 
Grade 2) and pneumonitis (≥ Grade 2), using published Lyman-
Kutcher-Burman normal tissue complication probabilities (LKB-
NTCP) models. The input parameters for the LKB models were 
D50 = 44.9, n = 0.34, m = 0.34 and D50 = 29.9, n = 1, m = 0.41 
for esophagitis and pneumonitis, respectively. The mean 
normalized total dose (NTD mean) of the PTV, and the mean dose 
to the esophagus (esophageal mean) and lung (lung mean) were 
determined.  
Results:  A total of 13 patients met our inclusion criteria and 
were analyzed, of which 11/13 had the GTV directly abutting the 
esophagus. The median [range] of the GTV and PTV were 90.6 cc 
[22.3 – 199.8] and 321.8 cc [164.1 – 564.9], respectively. Using 
ES-IMRT, the median esophageal mean and lung mean dose 
reduced from 17.0 and 7.9 Gy to 6.8 and 7.7 Gy, respectively. 
Using the LKB model, the theoretical probability of symptomatic 
esophagitis and pneumonitis reduced from 13 to 1%, and from 5 
to 3%, respectively. The median clinical POP NTDmean was 32.8 
Gy, while the median ES-IMRT NTDmean was 33.2 Gy.  
Conclusions:  Advanced radiotherapy techniques such as ES-IMRT 
may have clinical utility in reducing treatment-related toxicity 
in advanced lung cancer patients. Our data suggests that the rate 
of esophagitis can be reduced from 13 to 1%, without 
compromising tumour control. The results of this planning study 
will inform the design of a Phase II randomized controlled trial, 
Palliative Radiation of Advanced Central lung Tumours with 
Intentional Avoidance of the Esophagus (PROACTIVE). 
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Purpose: To document and evaluate outcomes of weekly, 
disease-site specific, radiation therapy (RT) peer review quality 
assurance (QA) rounds at a Canadian cancer centre.  
Methods and Materials: In compliance with Canadian 
Partnership for Quality Radiotherapy QA guidelines, seven 
disease-site specific, RT QA rounds were conducted by Radiation 
Oncologists (ROs) at a mid-sized cancer centre but outcomes 
were not formally categorized or documented. From January 6 
to May 5, 2015, outcomes of each case reviewed at (i) Breast, (ii) 
Head and Neck (including thyroid and cutaneous cases) and (iii) 
Lung tumour QA rounds were recorded prospectively. Each RT 
plan was assigned an outcome: A (no change required), B (issue 
to consider for future patients), or C (change required before 
next fraction). Following an initial audit, a standard 
nomenclature was developed and adopted by all seven disease-
site QA meetings from June 2015. 
Results: Two hundred and eleven RT plans prescribed by 20 ROs 
were peer reviewed at 43 QA meetings. Twenty-eight percent 
were reviewed after contouring (prior to plan development) and 
72% were reviewed after RO plan approval. For plans reviewed 
post-contouring, 26% had a ‘B’ and 10% had a ‘C’ outcome. For 
post-planning reviews, the ‘B’ and ‘C’ rates were 12% and 9%, 
respectively. Eighty-eight percent of ‘C’ outcomes resulted in 
plan changes prior to further RT. Only 55% of ‘C’ deviations 
would have been detected at the post-contouring stage. The 
most common reason for a B or C outcome was a 
recommendation for change in target volume definition. 
Adoption of this classification across all seven disease sites 
resulted in a global C outcome rate of 4%, among 732 cases 
reviewed between June and December 2015. 
Conclusions: Routine peer review of RT plans improved plan 
quality prior to treatment delivery. The optimal timing for QA 
meetings was deemed to be at the post-planning stage. 
Widespread successful rollout demonstrated the feasibility of the 
documentation approach across disease sites. 
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LARYNGEAL MOTION DYNAMICS USING 4D-COMPUTED 
TOMOGRAPHY AND DYNAMIC MAGNETIC RESONANCE IMAGING  
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Pensavan Thanomsack, Robert Doucet, Danis Blais, Louise 
Lambert 
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Purpose: To assess the dynamics of laryngeal motion in early 
glottic cancer in order to determine safe margins for partial 
larynx IMRT (PL-IMRT), as well as to evaluate dosimetric 
advantage of PL-IMRT.  
Methods and Materials: This prospective study included patients 
with T1-2N0 glottic cancer treated with whole larynx IMRT (WL-
IMRT). Pre- and mid-treatment 4D-CT allowed for assessment of 
larynx excursion during swallowing and in resting position. 
Sagittal MRI fluoroscopy was also obtained to assess swallowing 
frequency. For 10 patients, PL-IMRT plans were calculated using 
margins derived from 4D-CT analysis.  
Results: Twenty patients were accrued between 2015 and 2016. 
Over two minutes, median swallowing frequency was 1 (0-5) and 
was significantly reduced to 0 with instruction not to swallow. 
Median mid-treatment swallowing frequency was 0, even without 
specific instructions. Median amplitude of larynx excursion 
during swallowing was 23 mm (15-30), 1 mm (0-3), 6 mm (2-9) 
and 1 mm (0-3) in the superior, inferior, anterior and posterior 
directions, respectively, and remained similar mid-treatment. 
When not swallowing, median larynx excursion reached 4 mm (1-
6) and 2 mm (1-2) in superior-inferior and antero-posterior 
directions, respectively. 4D-CT analysis unexpectedly revealed 
that the planning CT had not been acquired in resting position in 
one patient. In up to 30% of patients, anatomic changes resulted 
in a 4 mm larynx shift in the SI direction and 2 mm in the AP 
direction in mid-treatment compared to pre-treatment imaging. 
PL-IMRT would have allowed for a relative reduction of mean 
doses to the ipsilateral carotid, contralateral carotid, 
contralateral arythenoid and larynx of 72%, 84%, 61% and 26%, 
respectively. Using an 8 mm ITV for PL-IMRT, swallowing would 
only result in CTV excursion beyond the 95% IDL for a median of 
0.8 seconds (0.2-1.8). 
